Free Trial
OTCMKTS:IZOZF

Izotropic Q1 2027 Earnings Results & Report

Izotropic logo
$0.12 -0.01 (-6.25%)
As of 03:28 PM Eastern

Izotropic missed analyst earnings expectations in its Q1 2027 results, released September 28, 2026. The company reported EPS of -$0.01 versus the $0.01 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2027
Time
After Market Closes

Izotropic EPS Results

Actual EPS
-$0.01
Consensus EPS
$0.01
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Izotropic Revenue Results

Actual Revenue
N/A
Expected Revenue
$2.03 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Izotropic Q1 2027 Earnings FAQ

Izotropic (OTCMKTS:IZOZF) reported earnings of -$0.01 per share for Q1 2027, missing the consensus estimate of $0.01. The report was announced on Monday, September 28, 2026.

Izotropic Earnings Headlines

The Iran War Isn’t Chaos. It’s Strategy.
Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congressmen no cameras, no staff. What he found afterward points to a coordinated Two-Front Economic War already in motion, according to his research at Behind the Markets.tc pixel
IZOZF making strides
See More Izotropic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Izotropic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Izotropic and other key companies, straight to your email.

About Izotropic

Izotropic (OTCMKTS:IZOZF) is a Canadian medical technology company focused on developing advanced breast-imaging solutions. The company’s principal product is the IzoView Breast CT Imaging System, a dedicated computed tomography platform designed to produce three-dimensional images of breast tissue.

IzoView is intended to support the detection, visualization and diagnosis of breast abnormalities by providing volumetric imaging rather than conventional two-dimensional views. The system is designed to image the breast without the compression used in traditional mammography, with the goal of improving the patient experience and helping clinicians evaluate complex breast tissue.

Izotropic is focused on the continued development, validation and potential commercialization of its technology for use in breast cancer screening and diagnostic imaging. The company is based in British Columbia, Canada, and its activities are directed toward medical-device markets serving healthcare providers and patients. Information regarding broad commercial deployment and current executive leadership is limited.

View Izotropic Profile